Knowing that patients who did not achieve pCR have worse BC outcomes, the phase III KATHERINE trial attempted to improve relapse rates in HER2+ BC patients who had pRD on the surgical specimen following taxane-based NAC (with or without anthracycline) plus trastuzumab. Here, ERBB2 is linked to breast cancer.